In short
Clinical trials are investigating Imipenem in several patient groups with serious infections. These studies look at how well treatment works, how safe it is, and whether it can reduce antibiotic use or improve outcomes. The trials include adults with pneumonia, urinary tract infections, febrile neutropenia, liver abscess, and critically ill patients.
Key points
- Clinical trials of Imipenem are being done in several serious infection settings, including pneumonia, febrile neutropenia, pyogenic liver abscess, urinary tract infection, and critically ill patients. Most of the studies are Phase 3 trials, with one Phase 2 study in Mycobacterium abscessus lung disease. The target groups are mostly adults with severe or hard-to-treat infections. The main study goals include treatment success, survival, infection clearance, fewer complications, and shorter use of broad-spectrum antibiotics. Some trials also measure antibiotic blood levels to see whether treatment exposure is adequate.
Clinical trial overview
The available studies investigate Imipenem in real clinical research settings, mostly for serious infections in adults. These trials do not focus on the drug itself as a textbook topic; they study how it performs in patients, often compared with other antibiotics or treatment strategies.
Most of the listed studies are Phase 3 trials, which means they test treatment effects in larger groups and compare outcomes between study arms. One study is Phase 2 and looks at treatment choices for Mycobacterium abscessus lung disease.
Infections and patient groups studied
The trials cover several infection types, showing that Imipenem is being studied in many severe or hard-to-treat situations.
- Hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia: one Phase 3 study compares an Imipenem-based treatment with another regimen in adults with these lung infections caused by Gram-negative bacteria.
- Febrile neutropenia: one Phase 3 study in hematology patients asks whether stopping antibiotics after 3 days is as safe as longer treatment. Imipenem is one of the antibiotics used in the study.
- Pyogenic liver abscess: one Phase 3 non-inferiority trial studies whether 3 weeks of antibiotic therapy after drainage is not worse than 6 weeks. Imipenem/cilastatin/relebactam is one of the treatment options listed.
- Febrile urinary tract infection: one Phase 2 trial studies oral follow-up treatment after initial therapy, and Imipenem/cilastatin is listed among the comparator treatments.
- Severe infections: one Phase 3 study tests a strategy that uses procalcitonin guidance and molecular-guided diagnosis to reduce unnecessary broad-spectrum antibiotic days; Imipenem is among the antibiotics used in the trial.
- Mycobacterium abscessus pulmonary disease: one Phase 2 study looks at the best treatment for this lung disease and includes Imipenem in the treatment options.
- Complicated urinary tract infection, acute pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, and complicated intra-abdominal infection: one Phase 3 study in adults with carbapenem-resistant Enterobacterales includes an Imipenem/cilastatin/relebactam arm.
- Critically ill patients with serious infections: one Phase 3 study measures antibiotic blood levels, and Imipenem/cilastatin/relebactam is among the antibiotics studied.
Trial designs, phases, and sizes
The studies use different designs, including randomized trials, comparative trials, non-inferiority trials, and interventional studies.
Enrollment sizes range from 150 patients in one completed trial to 1250 patients in the intensive care study, so the research includes both moderate and very large groups. The largest studies are designed to give stronger evidence about how well treatment works in real patient groups.
Some studies compare Imipenem-containing regimens with other antibiotic options, while others use it as one of several possible treatments in a broader strategy.
Main outcomes being measured
The main outcomes are focused on patient benefit, treatment success, and safety.
- Day 14 all-cause mortality: one pneumonia trial measures death from any cause by day 14 after randomization.
- Broad-spectrum antibiotic days: one severe infection trial measures how many days patients receive broad-spectrum antibiotics, with the goal of reducing unnecessary exposure.
- Overall treatment success at TOC: one trial in carbapenem-resistant Enterobacterales infections uses a composite endpoint, meaning it combines several infection-specific results into one main measure.
- Microbiological clearance: the Mycobacterium abscessus study checks whether cultures become negative after treatment, which means the germ is no longer found in sputum or bronchoalveolar lavage samples.
- Serious medical complications: the febrile neutropenia study checks for death, ICU admission, or septic shock needing vasopressive therapy within 42 days.
- Treatment failure after drainage: the liver abscess study measures whether patients have treatment failure between the end of treatment and week 12 after drainage.
- Clinical response at test of cure: the febrile UTI study looks for no new healthcare contacts or extra antibiotics, fever resolution, and symptom improvement 7 days after treatment ends.
- Antibiotic plasma target: the intensive care study measures whether blood concentrations reach the planned target levels for each antibiotic.
What these studies mean for patients
These trials show that Imipenem is being studied in patients who are often very sick and may have infections that are difficult to treat.
Some studies ask whether a shorter antibiotic course is enough, while others compare different treatment combinations or look for the best way to guide therapy.
In simple terms, the research is trying to find out which treatment plan gives the best balance between helping the infection and avoiding unnecessary antibiotic use.
Key terms explained
Non-inferiority means a study is checking whether a shorter or different treatment is not meaningfully worse than the standard approach. Composite endpoint means several results are combined into one main outcome, such as treatment success across many infection types.
Modified Intent-to-Treat population is the group used for the main analysis after applying study rules about who counts in the final results. Test of cure is a follow-up visit or time point used to judge whether the infection has responded to treatment.
CTCAE grades are a standard way to rate how severe side effects are, from mild to very serious. Procalcitonin guidance means treatment decisions are guided by a blood marker linked to infection activity.